Compare Stocks: ENTA, RAPP, CALT, and CMPS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CMPS Compass Pathways	$8.60 +0.1%	$12.57	$4.88 ▼ $15.87	$1.19B	2.43	3.31 million shs	5.25 million shs
ENTA Enanta Pharmaceuticals	$10.65 +2.7%	$12.33	$10.06 ▼ $17.15	$302.03M	0.75	234,017 shs	251,488 shs
RAPP Rapport Therapeutics	$25.93 +1.9%	$35.26	$22.06 ▼ $52.93	$1.22B	1.4	1.47 million shs	956,003 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CMPS Compass Pathways	+0.12%	-29.97%	-25.86%	-36.53%	+29.71%
ENTA Enanta Pharmaceuticals	+2.70%	-7.79%	-15.48%	-20.16%	-1.48%
RAPP Rapport Therapeutics	+1.93%	+15.24%	-19.45%	-44.06%	-2.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CMPS Compass Pathways	$8.60 +0.1%	$12.57	$4.88 ▼ $15.87	$1.19B	2.43	3.31 million shs	5.25 million shs
ENTA Enanta Pharmaceuticals	$10.65 +2.7%	$12.33	$10.06 ▼ $17.15	$302.03M	0.75	234,017 shs	251,488 shs
RAPP Rapport Therapeutics	$25.93 +1.9%	$35.26	$22.06 ▼ $52.93	$1.22B	1.4	1.47 million shs	956,003 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CMPS Compass Pathways	+0.12%	-29.97%	-25.86%	-36.53%	+29.71%
ENTA Enanta Pharmaceuticals	+2.70%	-7.79%	-15.48%	-20.16%	-1.48%
RAPP Rapport Therapeutics	+1.93%	+15.24%	-19.45%	-44.06%	-2.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CMPS Compass Pathways	2.88	Moderate Buy	$23.14	169.10% Upside
ENTA Enanta Pharmaceuticals	2.50	Moderate Buy	$19.00	78.40% Upside
RAPP Rapport Therapeutics	3.00	Buy	$67.18	159.09% Upside

Current Analyst Ratings Breakdown

Latest ENTA, RAPP, CALT, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/4/2026	RAPP Rapport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$73.00
11/4/2026	CMPS Compass Pathways	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
11/4/2026	CMPS Compass Pathways	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$13.00 ➝ $10.00
11/3/2026	CMPS Compass Pathways	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$20.00
11/3/2026	CMPS Compass Pathways	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$25.00
10/21/2026	RAPP Rapport Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$51.00 ➝ $50.00
10/21/2026	RAPP Rapport Therapeutics	JonesTrading Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$50.00 ➝ $82.00
10/20/2026	RAPP Rapport Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/20/2026	RAPP Rapport Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$65.00 ➝ $70.00
10/20/2026	RAPP Rapport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy	$86.00
10/20/2026	RAPP Rapport Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
ENTA Enanta Pharmaceuticals	$65.32M	4.75	N/A	N/A	$3.03 per share	3.51
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$10.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-18.89%	-5.43%	N/A
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.41	N/A	N/A	N/A	-96.89%	-61.84%	-20.70%	11/16/2026 (Estimated)
RAPP Rapport Therapeutics	-$111.48M	-$3.04	N/A	N/A	N/A	N/A	-29.02%	-27.37%	N/A

Latest ENTA, RAPP, CALT, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/16/2026	Q4 2026	ENTA Enanta Pharmaceuticals	-$0.7240	N/A	N/A	N/A	$14.62 million	N/A
11/4/2026	Q3 2026	RAPP Rapport Therapeutics	-$1.20	-$0.84	+$0.36	-$0.84	$0.07 million	N/A
11/3/2026	Q3 2026	CMPS Compass Pathways	-$0.39	-$0.31	+$0.08	-$0.31	N/A	N/A
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	-$0.67	-$0.1605	-$0.67	$16.76 million	$14.36 million
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
8/5/2026	Q2 2026	RAPP Rapport Therapeutics	-$1.12	-$1.19	-$0.07	-$1.19	$2.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CMPS Compass Pathways	0.60	1.30	1.30
ENTA Enanta Pharmaceuticals	N/A	3.76	3.76
RAPP Rapport Therapeutics	N/A	15.72	15.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CMPS Compass Pathways	46.19%
ENTA Enanta Pharmaceuticals	94.99%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CMPS Compass Pathways	2.82%
ENTA Enanta Pharmaceuticals	11.48%
RAPP Rapport Therapeutics	12.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
CMPS Compass Pathways	156	138.48 million	134.57 million	Optionable
ENTA Enanta Pharmaceuticals	120	29.12 million	25.78 million	Optionable
RAPP Rapport Therapeutics	84	47.98 million	41.99 million	Optionable

ENTA, RAPP, CALT, and CMPS Headlines

Recent News About These Companies

Rapport Therapeutics (NASDAQ:RAPP) Issues Earnings Results, Beats Estimates By $0.36 EPS

November 4 at 3:40 PM | marketbeat.com

Rapport Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 4 at 1:56 PM | marketscreener.comM

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

November 4 at 7:37 AM | finance.yahoo.com

Rapport Therapeutics (NASDAQ:RAPP) Sees Large Volume Increase After Insider Buying Activity

November 4 at 1:21 AM | americanbankingnews.com

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 3 at 7:00 AM | globenewswire.com

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase ...

November 3 at 3:53 AM | finance.yahoo.com

Rapport Therapeutics (NASDAQ: RAPP) director buys $20.36 million of stock via funds

November 3 at 3:13 AM | americanbankingnews.com

Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading Volume on Insider Buying Activity

November 2 at 10:41 AM | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider James Healy Acquires 969,480 Shares

November 1, 2026 | americanbankingnews.com

Insider Buying: Rapport Therapeutics (NASDAQ:RAPP) Director Purchases $20,359,080.00 in Stock

October 31, 2026 | insidertrades.com

Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider James Healy Purchases 969,480 Shares

October 30, 2026 | marketbeat.com

Rapport Therapeutics Strengthens Capital Base with New Financing

October 30, 2026 | tipranks.com

Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note Raise

October 30, 2026 | finance.yahoo.com

Rapport Therapeutics (NASDAQ:RAPP) Shares Up 7.8% - Here's What Happened

October 29, 2026 | marketbeat.com

Rapport Therapeutics (RAPP) Set to Announce Quarterly Earnings on Thursday

October 29, 2026 | marketbeat.com

Rapport Therapeutics Launches $350 Mln Stock And Convertible Notes Offerings; Stock Down

October 28, 2026 | rttnews.com

Rapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock Down

October 28, 2026 | rttnews.com

Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year Low - Time to Sell?

October 28, 2026 | marketbeat.com

Rapport Therapeutics slides after pricing securities offerings

October 28, 2026 | seekingalpha.com

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

October 28, 2026 | globenewswire.com

Rapport Therapeutics Down on Stock and Note Offerings

October 27, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENTA, RAPP, CALT, and CMPS Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 11/3/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Compass Pathways NASDAQ:CMPS

$8.60 +0.01 (+0.12%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$8.66 +0.06 (+0.70%)

As of 11/4/2026 07:55 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Enanta Pharmaceuticals NASDAQ:ENTA

$10.65 +0.28 (+2.70%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$10.66 +0.00 (+0.05%)

As of 11/4/2026 07:30 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Rapport Therapeutics NASDAQ:RAPP

$25.93 +0.49 (+1.93%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$25.64 -0.29 (-1.10%)

As of 11/4/2026 07:54 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTA, RAPP, CALT, and CMPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTA, RAPP, CALT, and CMPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTA, RAPP, CALT, and CMPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTA, RAPP, CALT, and CMPS Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Compass Pathways NASDAQ:CMPS

Enanta Pharmaceuticals NASDAQ:ENTA

Rapport Therapeutics NASDAQ:RAPP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTA, RAPP, CALT, and CMPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTA, RAPP, CALT, and CMPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTA, RAPP, CALT, and CMPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTA, RAPP, CALT, and CMPS Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Compass Pathways NASDAQ:CMPS

Enanta Pharmaceuticals NASDAQ:ENTA

Rapport Therapeutics NASDAQ:RAPP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools